| Literature DB >> 36212749 |
Mert İlker Hayıroğlu1, Tufan Çınar2, Vedat Çiçek2, Ali Palice1, Görkem Ayhan1, Ahmet İlker Tekkeşin1.
Abstract
Objective: There is an evidence gap regarding the predictive accuracy of the triglyceride-glucose (TyG) index for long-term major adverse cardiovascular events (MACEs) in individuals with high cardiovascular risk. The aim of this investigation was to evaluate the predictive value of the TyG index for long-term MACEs in patients at high cardiovascular risk.Entities:
Keywords: Cardiovascular diseases; Cardiovascular risk; Glucose; Index; Triglyceride
Year: 2022 PMID: 36212749 PMCID: PMC9515730 DOI: 10.12997/jla.2022.11.3.280
Source DB: PubMed Journal: J Lipid Atheroscler ISSN: 2287-2892
Baseline characteristics, laboratory parameters, and echocardiographic findings of all patients
| Characteristics | Patients without incident MACEs (n=396) | Patients with incident MACEs (n=87) | ||
|---|---|---|---|---|
| Age (yr) | 58.0 (53.0–63.0) | 65.0 (61.0–68.0) | <0.001 | |
| Sex, male | 171 (43.2) | 64 (73.6) | <0.001 | |
| BMI (kg/m2) | 28.9 (25.8–32.6) | 28.4 (25.4–31.4) | 0.370 | |
| SBP (mmHg) | 142 (132–151) | 152 (143–159) | <0.001 | |
| DBP (mmHg) | 82 (72–90) | 86 (75–97) | 0.007 | |
| Heart rate (beat per min) | 76 (69–82) | 76 (69–83) | 0.874 | |
| Risk factors | ||||
| HT | 270 (68.2) | 75 (86.2) | 0.001 | |
| Diabetes mellitus | 164 (41.4) | 63 (72.4) | <0.001 | |
| Hyperlipidemia | 76 (19.2) | 26 (29.9) | 0.027 | |
| Smoking | 172 (43.4) | 41 (47.1) | 0.530 | |
| Echocardiographic data | ||||
| LVEF | 61 (60–63) | 61 (60–62) | 0.605 | |
| LAVI (mL/m2) | 29.0 (24.2–34.0) | 29.6 (24.4–35.5) | 0.886 | |
| LVMI (g/m2) | 85.5 (72.8–94.9) | 89.3 (81.6–97.6) | 0.063 | |
| Laboratory analysis | ||||
| FBG (mg/d) | 106 (97–126) | 132 (104–165) | <0.001 | |
| Creatinine (mg/dL) | 0.81 (0.74–0.91) | 0.86 (0.77–1.00) | 0.012 | |
| BUN (mg/dL) | 14 (13–18) | 15 (12–20) | 0.777 | |
| AST (U/L) | 20 (17–24) | 19 (16–23) | 0.219 | |
| ALT (U/L) | 21 (16–28) | 20 (15–28) | 0.840 | |
| LDL-C (mg/dL) | 134 (114–163) | 142 (122–161) | 0.598 | |
| HDL-C (mg/dL) | 43 (38–51) | 41 (35–48) | 0.013 | |
| TG (mg/dL) | 146 (106–202) | 189 (147–289) | <0.001 | |
| TyG index | 8.2 (5.6–11.7) | 12.6 (8.5–21.3) | <0.001 | |
| Hs-CRP (mg/dL) | 0.00 (0.00–0.30) | 0.00 (0.00–0.30) | 0.645 | |
| Hs-troponin (ng/mL) | 0.02 (0.01–0.03) | 0.02 (0.01–0.03) | 0.251 | |
| HbA1c (%) | 6.0 (5.7–6.5) | 6.5 (6.0–7.1) | <0.001 | |
| TSH (mIU/L) | 1.5 (1.0–2.2) | 1.3 (0.9–2.0) | 0.161 | |
| T4 (ng/dL) | 1.0 (0.9–1.0) | 1.0 (0.9–1.1) | 0.639 | |
| Long-term MACEs | ||||
| Non-fatal MI | 0 (0.0) | 66 (75.9) | ||
| PCI-ACBG | 0 (0.0) | 83 (95.4) | ||
| Cardiovascular mortality | 0 (0.0) | 18 (20.7) | ||
| Follow-up (mon) | 45 (41–48) | 43 (41–48) | ||
Continuous variables are presented as median (interquartile range), nominal variables are presented as frequency (%).
MACE, major adverse cardiovascular event; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HT, hypertension; DM, diabetes mellitus; LVEF, left ventricular ejection fraction; LAVI, left atrial volume index; LVMI, left ventricular mass index; FBG, fasting blood glucose; BUN, blood urea nitrogen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; TyG, triglyceride-glucose; hs-CRP, high-sensitive C-reactive protein; hs-troponin, high-sensitivity troponin; TSH, thyroid-stimulating hormone; MI, myocardial infarction; PCI, percutaneous coronary intervention; ACBG, aortocoronary bypass grafting.
Univariable and multivariable model for long-term major adverse cardiovascular events
| Characteristics | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Age | 1.125 (1.089–1.163) | <0.001 | 1.153 (1.114–1.194) | <0.001 |
| Male sex | 2.990 (1.856–4.817) | <0.001 | 3.848 (2.324–6.372) | <0.001 |
| SBP | 1.031 (1.018–1.045) | <0.001 | 1.030 (1.011–1.048) | 0.001 |
| DBP | 1.019 (1.005–1.034) | 0.008 | - | - |
| HT | 2.422 (1.317–4.456) | 0.004 | - | - |
| DM | 2.870 (1.793–4.592) | 0.001 | 2.862 (1.688–4.852) | <0.001 |
| TG* | 1.004 (1.003–1.006) | <0.001 | - | - |
| FBG* | 1.007 (1.004–1.010) | <0.001 | - | - |
| TyG index | 1.004 (1.002–1.015) | <0.001 | 1.003 (1.001–1.006) | 0.011 |
| Creatinine | 3.744 (1.143–12.258) | 0.029 | - | - |
| HDL-C | 0.980 (0.959–1.002) | 0.072 | - | - |
| HbA1c | 1.199 (1.064–1.352) | 0.003 | - | - |
All clinically relevant parameters were included in the model.
SBP, systolic blood pressure; DBP, diastolic blood pressure; HT, hypertension; DM, diabetes mellitus; TG, triglyceride; TyG, triglyceride-glucose; HDL-C, high-density lipoprotein cholesterol; HbA1c, hemoglobin A1c; HR, odds ratio; CI, confidence interval.
*These parameters were not included in the multivariable model as they are components of the TyG index.
Fig. 1(A) A ROC curve analysis of the TyG index for long-term MACEs for patients with high cardiovascular risk. (B) A ROC curve analysis of the TyG index in long-term MACEs for patients without diabetes who had high cardiovascular risk.
ROC, receiver operating characteristic; TyG, triglyceride-glucose; MACE, major adverse cardiovascular event; CI, confidence interval.
Fig. 2Kaplan-Meier survival analysis of long-term MACEs according to cut-off values determined through receiver operating characteristic curve analysis.
TyG, triglyceride-glucose; MACE, major adverse cardiovascular event.